TLIS News and Press, Talis Biomedical Corporation From 09/13/21

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) on behalf of Talis stockholders. Our investigation conce...

Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen Therapeutics (NASDAQ:QLGN) +18%. Azu...

Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, ...

MENLO PARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that effective immediately Brian Coe has stepped down as P...

Image source: The Motley Fool. Talis Biomedical (NASDAQ: TLIS) Q2 2021 Earnings Call Aug 10, 2021 , 4:30 p.m. ET Continue reading For further details see: Talis Biomedical (TLIS) Q2 2021 Earnings Call Transcript

Talis Biomedical Corporation (TLIS) Q2 2021 Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Emily Faucette – Senior Vice President-Corporate Communications and Investor Relations Brian Coe – Chief Executive Officer Doug Liu – Chief Operating Offic...

Talis Biomedical (NASDAQ:TLIS): Q2 GAAP EPS of -$2.51 misses by $1.64. Revenue of $0.1M Shares +1.7%. Press Release For further details see: Talis Biomedical EPS misses by $1.64

MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today reported financial results and business progress for the second quar...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter af...